Cargando…
Betrixaban for prevention of venous thromboembolism in acute medically ill patients
Venous thromboembolism (VTE) is a common, potentially preventable cause of morbidity and mortality among acute medically ill patients. More than half of VTE events in this population occur after hospital discharge. Thus, providing extended-duration VTE prophylaxis from in-hospital through the post-d...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6016607/ https://www.ncbi.nlm.nih.gov/pubmed/29977165 http://dx.doi.org/10.1093/eurheartj/suy017 |
_version_ | 1783334598697025536 |
---|---|
author | Beyer-Westendorf, Jan Verhamme, Peter Bauersachs, Rupert |
author_facet | Beyer-Westendorf, Jan Verhamme, Peter Bauersachs, Rupert |
author_sort | Beyer-Westendorf, Jan |
collection | PubMed |
description | Venous thromboembolism (VTE) is a common, potentially preventable cause of morbidity and mortality among acute medically ill patients. More than half of VTE events in this population occur after hospital discharge. Thus, providing extended-duration VTE prophylaxis from in-hospital through the post-discharge continuum may improve the quality of care in patients at risk of VTE. Betrixaban is a new oral, once-daily factor Xa inhibitor approved by the United States (US) Food and Drug Administration (FDA) for extended-duration prophylaxis of VTE in acute medically ill patients. The clinical efficacy and safety of betrixaban in acute medically ill patients perceived to be at high risk for VTE were evaluated in a large, randomized, double-blind, active-controlled, multinational clinical trial [Acute Medically Ill VTE Prevention With Extended Duration Betrixaban (APEX)]. Patients were randomized to receive subcutaneous enoxaparin (10 ± 4 days) or oral betrixaban (35–42 days) plus matching placebos. The primary efficacy outcome was a composite of asymptomatic proximal deep vein thrombosis and symptomatic VTE; the primary safety measure was major bleeding. Extended-duration betrixaban reduced VTE events without an increase in major bleeding in the modified intent-to-treat analysis. Post hoc analyses of the APEX trial provided further evidence to support the efficacy and safety of betrixaban in reducing all-cause ischaemic stroke, fatal or irreversible ischaemic or bleeding events, as well as reducing VTE-related rehospitalization. In summary, analyses of the APEX study demonstrated a positive benefit–risk profile for extended prophylaxis of VTE with betrixaban in acute medically ill patients. This is likely to have important public health and health economic implications. |
format | Online Article Text |
id | pubmed-6016607 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-60166072018-07-05 Betrixaban for prevention of venous thromboembolism in acute medically ill patients Beyer-Westendorf, Jan Verhamme, Peter Bauersachs, Rupert Eur Heart J Suppl Articles Venous thromboembolism (VTE) is a common, potentially preventable cause of morbidity and mortality among acute medically ill patients. More than half of VTE events in this population occur after hospital discharge. Thus, providing extended-duration VTE prophylaxis from in-hospital through the post-discharge continuum may improve the quality of care in patients at risk of VTE. Betrixaban is a new oral, once-daily factor Xa inhibitor approved by the United States (US) Food and Drug Administration (FDA) for extended-duration prophylaxis of VTE in acute medically ill patients. The clinical efficacy and safety of betrixaban in acute medically ill patients perceived to be at high risk for VTE were evaluated in a large, randomized, double-blind, active-controlled, multinational clinical trial [Acute Medically Ill VTE Prevention With Extended Duration Betrixaban (APEX)]. Patients were randomized to receive subcutaneous enoxaparin (10 ± 4 days) or oral betrixaban (35–42 days) plus matching placebos. The primary efficacy outcome was a composite of asymptomatic proximal deep vein thrombosis and symptomatic VTE; the primary safety measure was major bleeding. Extended-duration betrixaban reduced VTE events without an increase in major bleeding in the modified intent-to-treat analysis. Post hoc analyses of the APEX trial provided further evidence to support the efficacy and safety of betrixaban in reducing all-cause ischaemic stroke, fatal or irreversible ischaemic or bleeding events, as well as reducing VTE-related rehospitalization. In summary, analyses of the APEX study demonstrated a positive benefit–risk profile for extended prophylaxis of VTE with betrixaban in acute medically ill patients. This is likely to have important public health and health economic implications. Oxford University Press 2018-05 2018-05-09 /pmc/articles/PMC6016607/ /pubmed/29977165 http://dx.doi.org/10.1093/eurheartj/suy017 Text en Published on behalf of the European Society of Cardiology. © The Author(s) 2018. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Articles Beyer-Westendorf, Jan Verhamme, Peter Bauersachs, Rupert Betrixaban for prevention of venous thromboembolism in acute medically ill patients |
title | Betrixaban for prevention of venous thromboembolism in acute medically ill patients |
title_full | Betrixaban for prevention of venous thromboembolism in acute medically ill patients |
title_fullStr | Betrixaban for prevention of venous thromboembolism in acute medically ill patients |
title_full_unstemmed | Betrixaban for prevention of venous thromboembolism in acute medically ill patients |
title_short | Betrixaban for prevention of venous thromboembolism in acute medically ill patients |
title_sort | betrixaban for prevention of venous thromboembolism in acute medically ill patients |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6016607/ https://www.ncbi.nlm.nih.gov/pubmed/29977165 http://dx.doi.org/10.1093/eurheartj/suy017 |
work_keys_str_mv | AT beyerwestendorfjan betrixabanforpreventionofvenousthromboembolisminacutemedicallyillpatients AT verhammepeter betrixabanforpreventionofvenousthromboembolisminacutemedicallyillpatients AT bauersachsrupert betrixabanforpreventionofvenousthromboembolisminacutemedicallyillpatients |